BioFluidica

BioFluidica is a privately held biotechnology company that has developed a revolutionary platform enabling disease management and diagnosis through prognosis, all from a simple blood test. The BioFluidica microfluidic platform can capture and isolate disease biomarkers, such as Circulating Tumor Cells (CTC), and has been clinically validated. Its ability to scan whole blood for the first signs of a disease, finding the rarest biomarkers with unmatched sensitivity, means fulfilling the promise of a true liquid biopsy. BioFluidica is revolutionizing disease detection by bringing better samples to millions of people.